To study the effectiveness of vancomycin medicine treatment in patients who are likely to have gram positive bacterial infection admitted to medicine intensive care unit

Pharmacokinetics-Pharmacodynamics relationship of vancomycin in patients with suspected or proven Gram-positive bacterial infection admitted to medicine intensive care unit of tertiary care hospital - PK-PD

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2015/11/006393

Enrollment

Registered

2015-11-30

Start date

Unknown

Completion date

Unknown

Last updated

2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: null- Admitted to Medicine Intensive Care Unit with suspected or proven bacterial infection

Interventions

Intervention1: Vancomycin: Vancomycin a glycopeptide is one of the few antibiotics available to treat MRSA infection and infections caused by Gram-positive bacteria Intervention2: Vancomycin: Vancomyc

Eligibility

Inclusion criteria

Inclusion criteria: 1. Written, signed, dated and institutional ethics committee approved informed consent obtained from patients or legally acceptable representative before performing any screening procedures 2.Patients with suspected or proven Gram â?? positive bacterial infection

Exclusion criteria

Exclusion criteria: 1.Patients with hypersensitivity to vancomycin hydrochloride or any excipients of its formulation 2.Patient receiving vancomycin therapy 3.Participation in any investigational study within 30 days prior to screening

Design outcomes

Primary

Measure	Time frame
The results of present study will give data on the pharmacokinetics of single dose and steady state of vancomycin and provide its correlation with pharmacodynamics. Any difference of our from the reported literature will help in refining our dosing strategy for better treatment outcome in patients admitted to the MICU, particularly against notorious organisms like Methicillin-resistant S.aureus (MRSA)Timepoint: The outcome will be assessed at steady state pharmacokinetics (Day 3)	—

Measure

Time frame

The results of present study will give data on the pharmacokinetics of single dose and steady state of vancomycin and provide its correlation with pharmacodynamics. Any difference of our from the reported literature will help in refining our dosing strategy for better treatment outcome in patients admitted to the MICU, particularly against notorious organisms like Methicillin-resistant S.aureus (MRSA)Timepoint: The outcome will be assessed at steady state pharmacokinetics (Day 3)

—

Secondary

Measure	Time frame
To assess the clinical outcome with AUC:MIC ratioTimepoint: The clinical outcome will be assessed on patients last day stay of MICU	—

Countries

India

Contacts

Public ContactNitin Mali

Seth GS Medical College and KEM Hospital

nitinbmali85@gmail.com02224133767

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026